Autopsy report · NCT00817531

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

“terminated due to futility after interim analysis”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Baylor Breast Care Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Dasatinib

Participants

22

Sites

1

Countries

United States

Trials that died the same way

• Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism
  “Terminated because of futility to continue, after planned interim analysis.” (90% match in meaning)
• Plasmalyte Versus Saline in Trauma Patients
  “Premature termination due to futility following interim analysis” (87% match in meaning)
• Trial to Evaluate UltraSound in the Treatment of Tibial Fractures
  “Study was terminated due to futility” (77% match in meaning)
• CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
  “Study was terminated after the planned interim analysis as the pre-defined futility threshold was met” (76% match in meaning)
• The MONOVISC Hip Osteoarthritis Study
  “The results of the interim analysis indicate the futility criterion have been met, therefore enrollment was terminated.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.